Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial
OZR 30 mg demonstrated both immediate and sustained efficacy in MTX-IR patients with RA. Multivariate analysis suggested that both baseline inflammation and disease activity-represented by CRP and CDAI-may independently influence treatment response. However, residual confounding due to baseline disease activity cannot be completely excluded, and this remains a limitation of the present study.
Authors
- Yusuke Miyazaki (ORCID: https://orcid.org/0000-0001-5692-3881)
- Yoshiya Tanaka (ORCID: https://orcid.org/0000-0002-0807-7139)
- Nobuko Horiuchi
- Rumiko Matsumoto
- Shunsuke Okamoto (ORCID: https://orcid.org/0000-0002-9465-0375)
- Tsutomu Takeuchi (ORCID: https://orcid.org/0000-0003-1111-8218)
Institutions
- University of Occupational and Environmental Health Japan (JP)
- Keio University (JP)
- Taisho Pharmaceutical (Japan) (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- RMD Open
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/rmdopen-2025-005710
- Citations
- 3
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 5.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Ablynx
- Daiichi-Sankyo
- Eisai
- Astellas Pharma
- Pfizer Japan
- Chugai Pharmaceutical
- Eli Lilly Japan